Maravai LifeSciences Holdings, Inc. announced that On July 27, 2023, William Trey Martin, III assumed the role of Chief Executive Officer, as contemplated under the Company?s previously-reported CEO succession plan. Mr. Martin will continue to receive the same, previously-disclosed compensation package he had while serving as President of Maravai?s Biologics Safety Testing segment. Mr. Martin ceased serving as President of Maravai?s Biologics Safety Testing segment upon his appointment as CEO.

Prior to the aforementioned appointment, Mr. Martin, age 48, served as the Company?s President for its Biologics Testing operating division, a position to which he was appointed on December 5, 2022. Prior to that, he served as the Company?s CEO from September 30, 2022 to October 18, 2022, and was on a leave of absence from October 18, 2022 until his appointment as President of the Biologics Testing operating division. Prior to joining Maravai, Mr. Martin was Senior Vice President, New Business ?

Genomic Medicine at Danaher Corporation (Danaher), a global science and technology company, where he served as from July 2021 to July 2022. Mr. Martin joined Danaher in 2018 in connection with its acquisition of Integrated DNA Technologies (IDT), a supplier of custom nucleic acids, where he served as President of the IDT business under Danaher?s ownership from April 2018 to July 2021. Prior to the acquisition, Mr. Martin served in a variety of roles at IDT since March 1994 and was Chief Operating Officer at the time of the acquisition by Danaher.

Mr. Martin holds a Bachelor of Science degree in biochemistry from the University of Iowa.